Dynavax Technologies Corporation
(NASDAQ : DVAX)

( )
DVAX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.81%174.661.2%$575.79m
CELGCelgene Corporation
0.60%89.491.2%$535.84m
GILDGilead Sciences, Inc.
0.42%74.010.9%$421.63m
BIIBBiogen Inc.
-1.41%259.301.2%$416.64m
REGNRegeneron Pharmaceuticals, Inc.
0.56%316.012.7%$245.42m
INCYIncyte Corporation
-0.42%68.142.5%$245.05m
VRTXVertex Pharmaceuticals Incorporated
0.34%158.691.9%$226.49m
ALXNAlexion Pharmaceuticals, Inc.
0.05%107.832.0%$209.17m
NKTRNektar Therapeutics
-0.88%85.456.0%$201.71m
ILMNIllumina, Inc.
0.51%245.853.5%$184.02m
AAgilent Technologies, Inc.
0.74%68.051.5%$157.16m
ALNYAlnylam Pharmaceuticals, Inc
-1.66%95.869.8%$140.19m
BLUEBluebird Bio, Inc.
-1.32%168.2515.8%$127.75m
EXASExact Sciences Corporation
2.48%48.7025.7%$111.34m
BMRNBioMarin Pharmaceutical Inc.
-0.27%82.084.4%$104.77m

Company Profile

Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that uses toll-like receptor biology to discover and develop novel vaccines and therapeutics. The company's development programs are organized under its three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The firm's other products under pipeline are SD-101, DV1179 Autoimmune Disease and AZD1419 Asthma Therapy. Dynavax Technologies was founded by Lawrence M. Lichtenstein, Dennis A. Carson and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.